PT-141: Sexual Desire Enhancement Targeted for Women PT-141 is FDA-approved for premenopausal women with hypoactive sexual desire disorder (HSDD)
It can demonstrate the unique advantages of the combined medication in four aspects: synergistic enhancement of efficacy, reduction of toxicity and protection, reversal of drug resistance, and improvement of immunity, thus providing new ideas for optimizing tumor treatment strategies
Hormonal fluctuations also cause fat to accumulate in the stomach area and make it harder to maintain muscle mass
Our protocols are built on trust, transparency, and clinically responsible use
Afzelin showed strong anti-oxidant activity in DPPH radical scavenging experiment (Kim et al., 2008)
All prescription products available through Sprout Health require an online medical evaluation with an independent licensed healthcare provider, who will determine if treatment is appropriate